Zacks Investment Research downgraded shares of Nu Skin Enterprises (NYSE:NUS) from a hold rating to a sell rating in a research report report published on Monday, Zacks.com reports. They currently have $44.00 price objective on the stock.

According to Zacks, “Nu Skin’s shares have underperformed the industry in the past six months. Headwinds in Mainland China, a soft view for 2020 and currency fluctuations are prime deterrents. The recently completed 100-day government campaign in Mainland China to inspect offerings of the nutrition and direct sales industry led to adversities like limited sales meetings. This took a toll on the company’s third-quarter 2019 results, with revenues and earnings declining year over year. The company also issued a soft view for the fourth quarter and 2020, wherein adverse impacts from currency movements are likely to persist. Nevertheless, the company is on track with product launches and programs to strengthen sales leaders in Mainland China. Also, the company is committed toward boosting customer base, which grew 4% in the third quarter.”

NUS has been the topic of a number of other reports. ValuEngine raised Nu Skin Enterprises from a sell rating to a hold rating in a report on Wednesday, October 2nd. Jefferies Financial Group lowered Nu Skin Enterprises from a buy rating to a hold rating and set a $40.00 target price on the stock. in a report on Wednesday, July 17th. Pivotal Research restated a buy rating and issued a $70.00 price target on shares of Nu Skin Enterprises in a research note on Wednesday, August 7th. Stifel Nicolaus upgraded Nu Skin Enterprises from a sell rating to a hold rating and boosted their price target for the company from $38.50 to $45.00 in a research note on Tuesday, October 29th. Finally, DA Davidson set a $42.00 price target on Nu Skin Enterprises and gave the company a hold rating in a research note on Friday, October 11th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company’s stock. Nu Skin Enterprises presently has an average rating of Hold and a consensus price target of $50.63.

Shares of NUS stock traded down $0.43 during trading on Monday, reaching $39.07. 428,579 shares of the company’s stock were exchanged, compared to its average volume of 628,851. The company has a quick ratio of 1.24, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $2.21 billion, a PE ratio of 11.10, a PEG ratio of 1.39 and a beta of 0.75. Nu Skin Enterprises has a twelve month low of $35.03 and a twelve month high of $69.79. The firm’s fifty day moving average price is $42.68 and its 200-day moving average price is $45.08.

Nu Skin Enterprises (NYSE:NUS) last posted its earnings results on Tuesday, November 5th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.76 by $0.03. The business had revenue of $590.00 million for the quarter, compared to analyst estimates of $605.02 million. Nu Skin Enterprises had a return on equity of 23.52% and a net margin of 4.59%. The firm’s revenue was down 13.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.94 EPS. As a group, analysts anticipate that Nu Skin Enterprises will post 3.1 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 11th. Investors of record on Friday, November 29th will be paid a $0.37 dividend. The ex-dividend date is Wednesday, November 27th. This represents a $1.48 annualized dividend and a yield of 3.79%. Nu Skin Enterprises’s dividend payout ratio (DPR) is presently 42.05%.

In other news, insider Foulis Greg 500,000 shares of Nu Skin Enterprises stock in a transaction that occurred on Wednesday, November 6th. Insiders own 3.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in shares of Nu Skin Enterprises by 17.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,477,300 shares of the company’s stock valued at $72,860,000 after acquiring an additional 223,889 shares during the period. D. E. Shaw & Co. Inc. lifted its position in shares of Nu Skin Enterprises by 69.9% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 1,211,867 shares of the company’s stock valued at $59,769,000 after acquiring an additional 498,564 shares during the period. AQR Capital Management LLC lifted its position in shares of Nu Skin Enterprises by 12.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,003,686 shares of the company’s stock valued at $49,331,000 after acquiring an additional 108,360 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Nu Skin Enterprises by 3.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 750,814 shares of the company’s stock valued at $37,030,000 after acquiring an additional 25,034 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its position in shares of Nu Skin Enterprises by 6.0% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 576,970 shares of the company’s stock valued at $28,456,000 after acquiring an additional 32,570 shares during the period. Hedge funds and other institutional investors own 74.02% of the company’s stock.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic and personal care products.

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Get a free copy of the Zacks research report on Nu Skin Enterprises (NUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.